Table1_Investigating the immune mechanism of natural products in the treatment of lung cancer.XLSX

With the deepening of people’s understanding of lung cancer, the research of lung cancer immunotherapy has gradually become the focus of attention. As we all know, the treatment of many diseases relies on the rich sources, complex and varied compositions and wide range of unique biological properties of natural products. Studies have shown that natural products can exert anticancer effects by inducing tumor cell death, inhibiting tumor cell proliferation, and enhancing tumor cell autophagy. More notably, natural products can adjust and strengthen the body’s immune response, which includes enhancing the function of NK cells and promoting the differentiation and proliferation of T lymphocytes. In addition, these natural products may enhance their anticancer effects by affecting inhibitory factors in the immune system, hormone levels, enzymes involved in biotransformation, and modulating other factors in the tumor microenvironment. The importance of natural products in lung cancer immunotherapy should not be underestimated. However, the specific links and correlations between natural products and lung cancer immunity are not clear enough, and further studies are urgently needed to clarify the relationship between the two. In this paper, we will focus on the correlation between natural products and lung cancer immune responses, with a view to providing new research perspectives for immunotherapy of lung cancer.</p

Optimization of culture conditions for <i>Ba</i>NPR production in <i>Bacillus amyloliqufaciens</i> 110N-6.

<p>a Effect of temperature on enzyme production. b Effect of pH on enzyme production. c Effect of working volume on enzyme production. d Effect of inoculum size on enzyme production. e Effect of different amino acids on enzyme production. f Effect of different metal ions on enzyme production. Each value in the panel represents the means ± SD (n = 3).</p

Multiple amino acid sequence alignment of NPR.

<p>Amino acid sequence alignment of <i>Ba</i>NPR from <i>Bacillus amyloliquefaciens</i> K11 with the NPR from <i>Bacillus amyloliquefaciens</i> Y2, NPRE from <i>Bacillus amyloliquefaciens</i> (<i>Bacillus velezensis</i>) (P06832), NPRE from <i>Bacillus subtilis</i> 168 (P68736), NPRE from <i>Bacillus cereus</i> (P05806), THER from <i>Bacillus thermoproteolyticus</i> (P00800), and NPRE from <i>Bacillus caldolyticus</i> (P23384) using the ClustalW program. Two histidine residues in active site are indicated by asterisks.</p

SDS-PAGE analysis of recombinant <i>Ba</i>NPR in <i>Bacillus amyloliquefaciens</i> K11.

<p>Lane: M, the molecular mass standards; 1–3 and 5–7, the different transformants harboring pUB110-<i>Banpr</i>; 4, the transformant harboring the empty vector pUB110.</p

A new illudane sesquiterpene from the edible fungus <i>Pholiota nameko</i>

Fungi have different genetic expression abilities and biosynthetic pathways under different cultivation conditions, which can produce various secondary metabolites. The “one strain many compounds” strategy is used to activate silent biosynthetic genes of fungi to produce various compounds, which is an effective method. In order to discover various new compounds in the edible fungus Pholiota nameko, a fermentation strategy involving precursor feeding and enzyme inhibitor addition has been employed. A new illudane sesquiterpene (1), along with one known indole diterpenoid alkaloid, cladosporine A (2) were isolated from the extracts of liquid culture of P. nameko. The new compound was identified by combination of 1D and 2D NMR, MS, optical rotation, and ECD calculations. We conducted experiments on the cytotoxicity of all isolated compounds on three cancer cell lines, but we did not observe any significant cytotoxicity (IC50 > 40 μM).</p

DataSheet_1_Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.docx

BackgroundImmune checkpoint inhibitors (ICIs) have left a deep impression in the treatment of non-small cell lung cancer (NSCLC), however, not all patients benefit from it. The purpose of this study was to investigate the prognostic value of baseline bone mineral density (BMD) derived from chest computed tomography (CT) scans in NSCLC patients treated with ICIs.MethodsThis study included patients with advanced NSCLC who underwent ICI treatment at the Wuhan Union Hospital from March 2020 to October 2022. Baseline BMD was evaluated at non-contrast chest CT at the level of first lumbar vertebra. Patients were divided into BMD-lower group and BMD-higher group according to the optimal cutoff value calculated by X-tile software. Baseline characteristics of the two groups were compared and variables between the two groups were balanced by propensity score matching (PSM) analysis. We calculated the objective response rate (ORR) and disease control rate (DCR) of the two groups and analyzed overall survival (OS) and progression-free survival (PFS) using BMD and other clinical indexes through Cox regression models and Kaplan-Meier survival curves.ResultsA total of 479 patients were included in this study, and all patients were divided into BMD-lower group (n=270) and BMD-higher group (n=209). After PSM analysis, each group consisted of 150 patients. ORR (43.3% vs. 43.5% before PSM, P = 0.964; 44.7% vs. 44.7% after PSM, P = 1.000) and DCR (91.1% vs. 94.3% before PSM, P = 0.195; 93.3% vs. 96.7% after PSM, P =0.190) were similar in two groups. There was no statistically significant relationship between BMD degree and PFS before (16.0 months vs. 18.0 months, P = 0.067) and after PSM analysis (17.0 months vs. 19.0 months, P = 0.095). However, lower BMD was associated with shorter OS both before (20.5 months vs. 23.0 months, PConclusionLower baseline BMD is associated with worse clinical outcomes in NSCLC patients treated with ICIs. As a reliable and easily obtained individual prognostic biomarker, BMD can become a routine detection indicator before immunotherapy.</p

Chemical constituents from <i>Piper wallichii</i>

<div><p>Fifteen known compounds including four triterpenoids (<b>1</b>–<b>4</b>), one sterol (<b>5</b>), one diketopiperazine alkaloid (<b>6</b>) and nine phenolics (<b>7</b>–<b>15</b>) were isolated from the stems of <i>Piper wallichii</i>. Their structures were elucidated by means of spectroscopic analysis, and acidic hydrolysis in case of the 2-oxo-3β,19α,23-trihydroxyurs-12-en-28-oic acid β-D-glucopyranosyl ester (<b>1</b>). The structure of compound <b>1</b> was fully assigned by 1D and 2D NMR experiments for the first time. All isolates were tested for their antibacterial, antifungal, anti-inflammatory and antiplatelet aggregation bioactivities.</p></div